The standard test for the diagnosis of narcolepsy is the multiple sleep latency test (MSLT). The MSLT is a complex test to perform as well as to interpret. The orexin-A/hypocretin-1 test is a sensitive and specific alternative to the MSLT to diagnose type 1 narcolepsy.
A Clinical Perspective
Michael Silber, M.B., Ch.B., a neurologist in the sleep medicine department at Mayo Clinic, provides a clinical perspective of narcolepsy, discussing limitations of current testing methods and the advantages of ordering the orexin-A/hypocretin-1 test.
Suresh Kotagal, M.D., a pediatric neurologist at Mayo Clinic, discusses how he uses the orexin-A/hypocretin-1 test in his practice.
A Laboratory Perspective
The Stanford Sleep Diagnostic Center was a pioneer of this assay and helped lay the groundwork for the development of this test. Joshua Bornhorst, Ph.D., a director in the clinical biochemistry laboratory at Mayo Clinic, discusses this test from a laboratory perspective and explains the role Mayo Clinic played in the development and validation of this test.
When to Order
- To aid in the diagnosis and differentiation of type 1 narcolepsy from other causes of hypersomnolence.
- This assay is not intended for use as a screening test.
Patient Preparation: Patient should not have recently received radioisotopes, either therapeutically or diagnostically, due to potential assay interference.
Collection Container/Tube: Sterile vial
Submission Container/Tube: CSF in plain vial with no additives
Specimen Volume: 1.5 mL
Pediatric Volume: 0.5 mL minimum volume
1. Obtain aliquot from second collection vial (preferred, not required).
2. Hemolyzed specimens will give false-positive results. Specimens should be centrifuged to remove any red cells prior to shipping.
Tuesday, 8 a.m.